Ann: Imugene Presentation to Bell Potter Conference, page-72

Your point is actually so embarrassingly weak that I wasn't going to respond directly to it, but I just mentally can't get past how biased and unsubstantiated it is.

Confirmed pseudoprogression rates for CF33 is roughly 3-4% give or take. Established clinical pseudoprogression rates for approved and effective immunotherapy (like PD1/PDL1) are roughly 6% in systematic reviews. OV therapy pseudoprogression rates are similar to immunotherapy.

So you are confident that an established 6% pseudoprogression across thousands of patients in approved immunotherapy is going to translate to meaningful clinical responses in a large percentage of patients for CF33?

The evidence is clearly against you.

@IronPig speaking of invasive, I wonder how long the needle had to be to inject CF33 into the bile duct tissue. If CF33 was cheaper than alternatives, wouldn't that mean it's global market value was cheap and therefore a buyout would also be small....